The United States International Trade Commission concluded that Apple violated patent laws in relation to the ECG feature on the Apple Watch. This development was reported by 9to5Mac, a source widely cited in tech news circles.
The ruling points to a patent held by AliveCor, a medical device maker that claims ownership over the ECG technology embedded in Apple’s smartwatch. A formal ban on selling the watches in the United States will not take effect until the appeal process runs its course, leaving Apple a window to respond through its legal channels.
There is discussion about the potential withdrawal of certain Apple Watch models from US and Canadian markets, including the Series 8 and the Ultra. Since the Apple Watch 4, the devices have featured integrated cardiogram sensing, but the current regulatory status means inventory in stores could be affected as the case unfolds.
Background reports indicate that AliveCor first drafted a custom wristband for the Apple Watch in 2015 that included an ECG sensor. Although a partnership with Apple was anticipated, it did not materialize. Apple subsequently released the Apple Watch 4 in 2018 with a built in ECG capability, reinforcing the emphasis on heart monitoring in its wearable lineup.
Earlier discussions also touched on Apple patents around ringable wearables that could monitor pulse, oxygen levels, blood pressure, and other vital signs, signaling the company’s broader interest in expanding personal health sensing devices beyond the watch itself.